<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958031</url>
  </required_header>
  <id_info>
    <org_study_id>CVL-871-2001</org_study_id>
    <secondary_id>IND 150,086</secondary_id>
    <nct_id>NCT04958031</nct_id>
  </id_info>
  <brief_title>A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerevel Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerevel Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients&#xD;
      with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to one of two or more groups in parallel for the duration of the study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>â€¢ Double Blind: two or more parties are unaware of the intervention assignment (Blinded: Subject, Caregiver, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From first dose of study drug up to Week 16 (follow-up period)</time_frame>
    <description>Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) results</measure>
    <time_frame>Baseline up to Week 16 or early termination (ET)</time_frame>
    <description>Assessment of clinically significant changes in QT intervals measured by 12-lead ECG recording after the participant has been supine and at rest for at least 5 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results</measure>
    <time_frame>Baseline up to Week 14 or early termination (ET)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence in clinically significant changes in vital sign measurements</measure>
    <time_frame>Baseline up to Week 14 or early termination (ET)</time_frame>
    <description>Assessment of clinically significant changes in vital signs including temperature, systolic and diastolic blood pressure, and heart rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in physical and neurological examination results</measure>
    <time_frame>Screening up to Week 16 or early termination (ET)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant findings in suicidality assessed using the Columbia Suicide-Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline up to Week 14 (follow up period)</time_frame>
    <description>The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent.&quot; The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Dementia Apathy Interview and Rating (DAIR) score</measure>
    <time_frame>Baseline up to Week 12 or early termination (ET)</time_frame>
    <description>The Dementia Apathy Interview Rating (DAIR) is a 16-item structured interview with the primary caregiver designed to assess illness-related changes in motivation, emotional responsiveness, and engagement. The total apathy score is a sum of all items reflecting change (items for which there is no change are not rated), divided by the number of items completed, with higher scores representing greater average apathy. In addition, the frequency of these behaviors is assessed; higher scores represent more frequent apathy-related behavior.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Apathy in Dementia</condition>
  <arm_group>
    <arm_group_label>CVL-871 1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CVL-871 tablets orally QD up to the maximum dose of 1.0 milligrams (mg) until Day 85 during the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVL-871 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CVL-871 tablets orally QD up to the maximum dose of 3.0 milligrams (mg) until Day 85 during the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a placebo matched to CVL-871 tablets orally QD until Day 85 during the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVL-871 1.0 mg</intervention_name>
    <description>CVL-871 1.0 mg, oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-7)</description>
    <arm_group_label>CVL-871 1.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVL-871 3.0 mg</intervention_name>
    <description>CVL-871 3.0 mg QD oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-21)</description>
    <arm_group_label>CVL-871 3.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo QD, oral (tablet), once per day for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets diagnostic criteria for apathy in neurocognitive disorders clinically&#xD;
             significant apathy&#xD;
&#xD;
          -  Mild to Moderate Dementia (AD, FTD, VAD, or DLB)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other significant psychiatric disorder(s)&#xD;
&#xD;
          -  Other neurological disorders (other than AD, FTD, VAD, or DLB)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Diego, California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Silva</last_name>
      <phone>858-836-8779</phone>
      <email>miriam.silva@sharp.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Ana, California</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorrie Bisesi</last_name>
      <phone>714-542-3008</phone>
      <email>lbisesi@syrentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Haven, Connecticut</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Gunnoud</last_name>
      <phone>203-764-8100</phone>
      <email>carol.gunnoud@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Delray Beach, Florida</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Hudson</last_name>
      <phone>561-374-8461</phone>
      <email>ahudson@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami, Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliet Perez</last_name>
      <phone>305-392-0279</phone>
      <email>jperez@pcrinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami, Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Isesalaya</last_name>
      <phone>305-751-8626</phone>
      <email>misesalaya@miamijewishhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando, Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candice Montros</last_name>
      <phone>407-705-3471</phone>
      <email>candice.montros@headlandsresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wellington, Florida</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Brown</last_name>
      <phone>561-209-2400</phone>
      <email>cbrown@researchalz.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staten Island, New York</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priya Selvarajah</last_name>
      <phone>718-317-5522</phone>
      <email>pselvarajah@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abington, Pennsylvania</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Donofry</last_name>
      <phone>215-957-9250</phone>
      <email>alyssadonofry.ana@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allentown, Pennsylvania</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fairfax, Virginia</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Bland</last_name>
      <phone>703-520-9703</phone>
      <email>mbland@re-cognitionhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Apathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

